scispace - formally typeset
L

Lotus Mallbris

Researcher at Eli Lilly and Company

Publications -  102
Citations -  6730

Lotus Mallbris is an academic researcher from Eli Lilly and Company. The author has contributed to research in topics: Psoriasis & Psoriasis Area and Severity Index. The author has an hindex of 35, co-authored 102 publications receiving 5801 citations. Previous affiliations of Lotus Mallbris include Karolinska University Hospital & Karolinska Institutet.

Papers
More filters
Journal ArticleDOI

A Genome-Wide Association Study Identifies New Psoriasis Susceptibility Loci and an Interaction Between HLA-C and ERAP1

Amy Strange, +85 more
- 01 Nov 2010 - 
TL;DR: These findings implicate pathways that integrate epidermal barrier dysfunction with innate and adaptive immune dysregulation in psoriasis pathogenesis and report compelling evidence for an interaction between the HLA-C and ERAP1 loci.
Journal ArticleDOI

Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity

Lam C. Tsoi, +215 more
- 01 Dec 2012 - 
TL;DR: A meta-analysis of genome-wide association studies and independent data sets genotyped on the Immunochip identified 15 new susceptibility loci, increasing to 36 the number associated with psoriasis in European individuals, and identified five independent signals within previously known loci.

Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity

Lam C. Tsoi, +199 more
TL;DR: A meta-analysis of genome-wide association studies and independent data sets genotyped on the Immunochip identified 15 new susceptibility loci, increasing to 36 the number associated with psoriasis in European individuals, and identified five independent signals within previously known loci.
Journal ArticleDOI

Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients.

TL;DR: It is concluded that a diagnosis of psoriasis per se does not appear to increase the risk for cardiovascular mortality, however, severe Psoriasis, here measured as repeated admissions, and early age at first admission, is associated with increasedrisk for cardiovascular death.
Journal ArticleDOI

Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial.

TL;DR: Despite unmet need, 15 years have passed since a topical therapy with a new mechanism of action for atopic dermatitis (AD) has been approved.